Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas for which there is a significant unmet medical need. PTCLs are aggressive hematological tumors with a guarded prognosis. Patients are generally treated first-line with chemotherapy, which, unfortunately, has limited efficacy, as do other treatments, whose response rate generally does not exceed 30%.
The antibody developed by XENOTHERA , a Nantes-based biotech company specializing in the development of innovative treatments, recognizes most PTCLs. It is more effective than chemotherapy on T-cell lymphomas and has a significant antitumor effect, with a reduction of up to 90% in tumor size in preclinical in vivo models.
The European Medicines Agency (EMA) granted authorization for this Phase I/II trial in April 2024, thus confirming its interest in this innovative treatment for a serious condition.
The first centers participating in the trial are the University Hospitals of Caen Normandy, Bordeaux , Clermont-Ferrand , the AP-HP and the Hospices Civils de Lyon . The first patient was recruited at the University Hospital of Caen Normandy, more specifically within the Clinical Research Center , by the teams of Professor Gandhi Damaj , international coordinator of this study.
We thank this first patient and Professor Damaj's teams for their involvement and hope that the expected benefits will be confirmed!
